NTRB - NASDAQ

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%

HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$50.45M

EPS-0.9900

P/E Ratio-4.19

Earnings Date04/27/2026

7.47M

Assets

-1%

3Y-41.0%

5Y+240.0%

10Y+2263536.0%

1.04M

Total Liabilities

-4%

3Y+18.0%

5Y-49.0%

10Y+8722.0%

6.43M

Total Equity

3Y-46.0%

5Y+3565.0%

10Y-56151.0%

Nutriband Inc. Funding & Solvency Profile

NTRB · NASDAQ

Current Assets

Cash & Cash Equivalents4.31M

Net Receivables73.85K

Inventory212.04K

Other Current Assets-546.00

Total Current Assets5 M

Non-Current Assets

Property, Plant & Equipment695.06K

Goodwill & Intangible Assets1.98M

Long-Term Investments0.00

Other Non-Current Assets-63.00

Total Non-Current Assets695 K

Total Assets

7.47M

Financial Health Analysis

Current Ratio

4.88x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.16x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

4 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

64% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Nutriband Inc. Balance Sheet

NTRB • NASDAQ

Nutriband Inc. Balance Sheet	Jan 2025	Jan 2024	Jan 2023	Jan 2022	Jan 2021	Jan 2020	Jan 2019	Jan 2018	Jan 2017	Jan 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	4.3M	492.9K	2M	4.9M	152K	10.2K	474.7K	0.0	27.1K	100.0
Cash & Short-Term Investments	4.3M	492.9K	2M	4.9M	152K	10.2K	474.7K	0.0	27.1K	100.0
Net Receivables	73.8K	148.6K	113K	71.4K	109.3K	12.8K	13.1K	263.0	229.0	0.0
Accounts Receivables	73.8K	148.6K	113K	71.4K	109.3K	12.8K	13.1K	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	263.0	229.0	0.0
Inventory	212K	168.6K	229.3K	131.6K	52.8K	0.0	0.0	4.1K	8K	-230.0
Prepaids	196.7K	211.7K	365.9K	0.0	0.0	20.2K	102.7K	160.5K	2.3K	0.0
Other Current Assets	-546.0	0.0	0.0	370.5K	0.0	0.0	102.7K	0.0	0.0	0.0
Total Current Assets	4.8M	1M	2.7M	5.5M	314.2K	43.2K	590.5K	164.9K	37.7K	330.0
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	695.1K	806.3K	960.5K	998.3K	1.1M	120.6K	146.1K	0.0	0.0	0.0
Goodwill	1.7M	5M	5M	5.3M	7.5M	1.7M	1.7M	0.0	0.0	0.0
Intangible Assets	261.1K	667.3K	780.4K	926.9K	1M	314.7K	351.8K	0.0	0.0	0.0
Goodwill & Intangible Assets	2M	5.7M	5.8M	6.3M	8.5M	2M	2.1M	0.0	0.0	0.0
Other Non-Current Assets	-63.0	0.0	-6.8M	-7.3M	0.0	-2.2M	0.0	0.0	0.0	0.0
Total Non-Current Assets	2.7M	6.5M	6.8M	7.3M	9.6M	2.2M	2.2M	0.0	0.0	0.0
Total Assets	7.5M	7.5M	9.5M	12.7M	9.9M	2.2M	2.8M	164.9K	37.7K	330.0
LIABILITIES
CURRENT LIABILITIES
Total Payables	698.8K	680.1K	534.7K	639.5K	940.6K	771.9K	291.8K	12.3K	4.1K	1.2K
Accounts Payable	698.8K	680.1K	534.7K	639.5K	940.6K	771.9K	291.8K	12.3K	4.1K	1.2K
Accrued Expenses	0.0	0.0	-225.5K	-144.9K	-136.3K	0.0	0.0	0.0	0.0	0.0
Short Term Debt	128.1K	127.2K	51K	33.5K	1.5M	311.6K	40K	31.1K	10.5K	9.9K
Capital Lease Obligations (Current)	0.0	34.3K	31.3K	19.3K	24.7K	10.1K	0.0	0.0	0.0	0.0
Deferred Revenue	155.9K	157.5K	162.9K	106.3K	86.8K	0.0	71.2K	-43.4K	-4.1K	0.0
Other Current Liabilities	0.0	0.0	-31.3K	-19.3K	-24.7K	928.8K	0.0	0.0	0.0	0.0
Total Current Liabilities	982.8K	999.1K	748.6K	779.3K	2.6M	2M	403K	43.4K	14.6K	11.1K
NON-CURRENT LIABILITIES
Long Term Debt	58.2K	79.8K	100.5K	101.1K	246.9K	0.0	0.0	0.0	0.0	686.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	-96.8K	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	58.2K	79.8K	134.8K	101.1K	246.9K	0.0	0.0	0.0	0.0	686.0
Capital Lease Obligations	0.0	34.3K	65.6K	19.3K	121.5K	10.1K	0.0	0.0	0.0	0.0
Total Liabilities	1M	1.1M	883.4K	880.4K	2.8M	2M	403K	43.4K	14.6K	11.8K
SHAREHOLDERS' EQUITY
Treasury Stock	-149K	-32.6K	-32.6K	-104.5K	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	11.1K	8.9K	7.8K	7.8K	6.3K	5.4K	21.7K	20.9K	15.6K	21.9K
Additional Paid-In Capital	45M	34.4M	31.1M	30M	18.9M	9.1M	8.6M	3M	183.3K	-8.8K
Retained Earnings	-38.5M	-28M	-22.5M	-18M	-11.8M	-8.9M	-6.2M	-2.8M	-177.5K	-26.2K
Accumulated Other Comprehensive Income/Loss	-304.0	-304.0	-304.0	-304.0	-304.0	-304.0	-52.0	-446.0	1.7K	1.6K
Other Total Stockholders' Equity	0.0	0.0	0.0	1.3K	70K	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	6.4M	6.4M	8.6M	11.9M	7.1M	175.4K	2.4M	121.5K	23.1K	-11.5K
Total Equity	6.4M	6.4M	8.6M	11.9M	7.1M	175.4K	2.4M	121.5K	23.1K	-11.5K
SUMMARY
Total Liabilities & Equity	7.5M	7.5M	9.5M	12.7M	9.9M	2.2M	2.8M	164.9K	37.7K	330.0
Total Debt	186.3K	241.3K	185.8K	134.6K	1.8M	321.6K	40K	31.1K	10.5K	10.6K
Net Debt	-4.1M	-251.7K	-1.8M	-4.8M	1.6M	311.4K	-434.7K	31.1K	-16.7K	10.5K
Shares Outstanding	11,160,428	11,160,428	11,160,428	11,160,428	11,160,428	11,160,428	11,160,428	11,160,428	11,160,428	11,160,428

SEC Filings

NTRB - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	April 07, 2026	March 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 13, 2026	February 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 03, 2026	January 24, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 30, 2025	December 30, 2025	2025	View Filing
DEF 14A DEF 14A 2026 N/A	December 19, 2025	January 24, 2026	2026	View Filing
10-Q 10-Q 2025 Q4 Q4	December 11, 2025	October 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 28, 2025	October 28, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	September 09, 2025	July 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 03, 2025	February 01, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 07, 2025	August 05, 2025	2025	View Filing

Showing 1 to 10 of 141 filings

Related Guides

Blog Categories

Continue your NTRB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.